keyword
MENU ▼
Read by QxMD icon Read
search

Eye anti-VEGF

keyword
https://www.readbyqxmd.com/read/28526489/intravitreous-injection-of-aav2-sflt01-in-patients-with-advanced-neovascular-age-related-macular-degeneration-a-phase-1-open-label-trial
#1
Jeffrey S Heier, Saleema Kherani, Shilpa Desai, Pravin Dugel, Shalesh Kaushal, Seng H Cheng, Cheryl Delacono, Annie Purvis, Susan Richards, Annaig Le-Halpere, John Connelly, Samuel C Wadsworth, Rafael Varona, Ronald Buggage, Abraham Scaria, Peter A Campochiaro
BACKGROUND: Long-term intraocular injections of vascular endothelial growth factor (VEGF)-neutralising proteins can preserve central vision in many patients with neovascular age-related macular degeneration. We tested the safety and tolerability of a single intravitreous injection of an AAV2 vector expressing the VEGF-neutralising protein sFLT01 in patients with advanced neovascular age-related macular degeneration. METHODS: This was a phase 1, open-label, dose-escalating study done at four outpatient retina clinics in the USA...
May 16, 2017: Lancet
https://www.readbyqxmd.com/read/28520639/wrinkled-vascularized-retinal-pigment-epithelium-detachment-prognosis-after-intravitreal-anti-vegf-therapy
#2
Delphine Lam, Oudy Semoun, Rocio Blanco-Garavito, Camille Jung, Diem T Nguyen, Eric H Souied, Gerard Mimoun
BACKGROUND/PURPOSE: Neovascular age-related macular degeneration (nAMD) is frequently associated with vascularized pigment epithelial detachment (v-PED). We observed a peculiar characteristic of v-PED characterized by small lacy folds of the retinal pigment epithelium, appearing as a wrinkled PED (w-PED) on spectral domain optical coherence tomography (SD-OCT). Our purpose was to describe the visual prognosis and number of intravitreal injections in w-PED compared with non-w-PED. METHODS: In this retrospective, case-control series, we reviewed retrospectively medical records of 52 eyes of 51 patients who were consecutively included between November 1 and 30, 2015 with a previous minimum 3-year follow-up...
May 16, 2017: Retina
https://www.readbyqxmd.com/read/28513493/inflammatory-choroidal-neovascularization-in-indian-eyes-etiology-clinical-features-and-outcomes-to-anti-vascular-endothelial-growth-factor
#3
Rupak Roy, Kumar Saurabh, Aditya Bansal, Amitabh Kumar, Anindya Kishore Majumdar, Swakshyar Saumya Paul
BACKGROUND AND OBJECTIVES: The aim was to study the clinical profile of inflammatory choroidal neovascularization (CNV) and its treatment response to intravitreal bevacizumab or ranibizumab on pro re nata (PRN) basis in Indian eyes. MATERIALS AND METHODS: This was a retrospective case series of consecutive patients with inflammatory CNV treated with anti-vascular endothelial growth factor (anti-VEGF) in a tertiary eye care center in Eastern India between 2009 and 2014...
April 2017: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/28512425/long-term-follow-up-of-polypoidal-choroidal-vasculopathy-secondary-to-angioid-streaks-treated-by-intravitreal-aflibercept-and-ranibizumab
#4
James G Wong, Katherine Yu Qian
PURPOSE: Angioid streaks (AS) are dehiscences in Bruch's membrane that may be idiopathic or associated with numerous systemic illnesses. Polypoidal choroidal vasculopathy (PCV) is an underdiagnosed exudative chorioretinopathy often characterised by serosanguineous detachments of the pigmented epithelium. The use of the anti-VEGF agents ranibizumab and aflibercept in the management of PCV secondary to AS has not been previously documented. We report 3 patients with active PCV secondary to AS, 1 of which had a family history of PCV secondary to AS, not previously reported in the literature...
January 2017: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/28503435/evaluation-of-hyperreflective-foci-as-a-prognostic-factor-of-visual-outcome-in-retinal-vein-occlusion
#5
Bin Mo, Hai-Ying Zhou, Xuan Jiao, Feng Zhang
AIM: To evaluate the potential role of hyperreflective foci (HF) as a prognostic indicator of visual outcome in patients with macular edema (ME) due to retinal vein occlusion (RVO). METHODS: We retrospectively reviewed 50 eyes of 50 patients with ME due to ischemic central retinal vein occlusion (CRVO), non-ischemic CRVO and branch retinal vein occlusion (BRVO) who were treated with anti-vascular endothelial growth factor (anti-VEGF) at Beijing Tongren Eye Center from January 2013 to July 2016...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28499163/the-diabetic-retinopathy-barometer-study-global-perspectives-on-access-to-and-experiences-of-diabetic-retinopathy-screening-and-treatment
#6
D Cavan, L Makaroff, J da Rocha Fernandes, M Sylvanowicz, P Ackland, J Conlon, D Chaney, A Malhi, J Barratt
AIM: To assess the level of awareness, prevention and treatment of Diabetic Eye Disease (DED) comprising Diabetic Retinopathy (DR) and Diabetic Macula Edema (DME) retinopathy among adults with diabetes and health professionals. METHODS: The Diabetic Retinopathy Barometer Study consisted of a qualitative study, which consisted of semi-structured interviews, and a quantitative study using online surveys for adults with diabetes and for health professionals. RESULTS: A total of 4340 adults with diabetes and 2329 health professionals participated in the surveys...
April 4, 2017: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/28499051/safety-and-efficacy-of-ziv-aflibercept-in-the-treatment-of-refractory-diabetic-macular-edema
#7
Mohammed Ashraf, Hassan El Kayal, Ahmed A R Souka
BACKGROUND AND OBJECTIVE: To evaluate the safety and efficacy of ziv-aflibercept (Zaltrap; Sanofi-Aventis, Bridgewater, NJ/Regeneron Pharmaceuticals, Tarrytown, NY) in the treatment of refractory diabetic macular edema (DME). PATIENTS AND METHODS: Retrospective case series looking at the safety of ziv-aflibercept in patients with DME refractory to previous anti-vascular endothelial growth factor (VEGF) therapy. Detailed ophthalmologic examination, best-corrected visual acuity, and optical coherence tomography measurements were performed pre-switch, as well as at each monthly follow-up visit...
May 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28496299/response-of-eyes-with-age-related-macular-degeneration-to-anti-vegf-drugs-and-implications-for-therapy-planning
#8
Noriko Miyamoto, Michiko Mandai, Hiroshi Kojima, Takanori Kameda, Masataka Shimozono, Akihiro Nishida, Yasuo Kurimoto
PURPOSE: To evaluate the response to and dependence on aflibercept or ranibizumab in patients with age-related macular degeneration (AMD). METHODS: We retrospectively reviewed AMD patients who received induction therapy with aflibercept or ranibizumab for the following parameters: whether complete resolution of the retinal fluid ("good response") was achieved and whether recurrence was observed within 3 months ("dependent") after the induction treatment. With aflibercept treatment, treatment-naïve eyes with a good response/non-dependence were recommended a pro re nata regimen, and other eyes were recommended a proactive bimonthly regimen, followed by monitoring of visual acuity (VA) for 12 months...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28494491/topical-delivery-of-anti-vegf-drugs-to-the-ocular-posterior-segment-using-cell-penetrating-peptides
#9
Felicity de Cogan, Lisa J Hill, Aisling Lynch, Peter J Morgan-Warren, Judith Lechner, Matthew R Berwick, Anna F A Peacock, Mei Chen, Robert A H Scott, Heping Xu, Ann Logan
Purpose: To evaluate the efficacy of anti-VEGF agents for treating choroidal neovascularization (CNV) when delivered topically using novel cell-penetrating peptides (CPPs) compared with delivery by intravitreal (ivit) injection. Methods: CPP toxicity was investigated in cell cultures. Ivit concentrations of ranibizumab and bevacizumab after topical administration were measured using ELISA. The biological efficacy of topical anti-VEGF + CPP complexes was compared with ivit anti-VEGF injections using an established model of CNV...
May 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28492860/baseline-factors-associated-with-6-month-visual-acuity-and-retinal-thickness-outcomes-in-patients-with-macular-edema-secondary-to-central-retinal-vein-occlusion-or-hemiretinal-vein-occlusion-score2-study-report-4
#10
Ingrid U Scott, Paul C VanVeldhuisen, Michael S Ip, Barbara A Blodi, Neal L Oden, Jacqueline King, Andrew N Antoszyk, Mark A Peters, Michael Tolentino
Importance: Macular edema (ME) is the leading cause of decreased visual acuity (VA) associated with retinal vein occlusion (RVO). Identifying factors associated with better outcomes in RVO eyes treated with anti-vascular endothelial growth factor (VEGF) therapy may provide information useful in counseling patients. Objective: To investigate baseline characteristics associated with 6-month VA and central subfield thickness (CST) outcomes in participants in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)...
May 9, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/28492427/quantitative-optical-coherence-tomography-analysis-of-retinal-degenerative-changes-in-diabetic-macular-edema-and-neovascular-age-related-macular-degeneration
#11
Ernest V Boiko, Dmitrii S Maltsev
PURPOSE: To investigate the relationship of the pre-anti-vascular endothelial growth factor (VEGF) retinal tissue area (RTA) and optical density (ODRT) of the retinal optical slice portion located in the central subfield, and their ratio (RTA/ODRT), in the presence of diabetic macular edema or of inraretinal cystic fluid in neovascular age-related macular degeneration, to central retinal thickness and best-corrected visual acuity after anti-VEGF treatment with ME resolution. METHODS: The optical coherence tomography images and medical records of 33 patients (41 eyes) with neovascular age-related macular degeneration, 15 (21 eyes) with diabetic macular edema and 9 healthy individuals (15 eyes) were retrospectively analyzed...
May 10, 2017: Retina
https://www.readbyqxmd.com/read/28470332/retinal-oxygen-saturation-correlates-with-visual-acuity-but-does-not-predict-outcome-after-anti-vegf-treatment-in-central-retinal-vein-occlusion
#12
Signe Krejberg Jeppesen, Toke Bek
Purpose: Occlusion of the central retinal vein (CRVO) is a frequent cause of visual loss. The occlusion induces hypoxia in the retina and the larger retinal veins, but the significance of retinal oxygen saturation for visual acuity at diagnosis and after anti-VEGF treatment for CRVO has not been studied in detail. Methods: Retinal oximetry was performed in 91 patients consecutively referred for specialist evaluation of CRVO. The correlation between oxygen saturation in larger retinal vessels and visual acuity at the primary examination and the predictive value of oxygen saturation for visual prognosis after three monthly intravitreal injections with anti-VEGF medication were studied...
May 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28458584/anti-vegf-therapy-for-central-retinal-vein-occlusion-caused-by-tuberculosis-associated-uveitis-a-case-report
#13
Manzo Taguchi, Yutaka Sakurai, Takayuki Kanda, Masaru Takeuchi
BACKGROUND: Tuberculosis (TB)-associated uveitis presents periphlebitis, occasionally causing central retinal vascular occlusion (CRVO). Intravitreal injection of ranibizumab (IVR) is an effective treatment for CRVO, which improves macular edema (ME) by reducing vascular permeability and prevents progression of retinal nonperfusion in CRVO. We report a case of CRVO due to TB-associated uveitis, which initially remitted by repeated IVR as an adjunct to anti-TB therapy and systemic corticosteroids, but subsequently led to severe vitreous hemorrhage (VH)...
2017: International Medical Case Reports Journal
https://www.readbyqxmd.com/read/28448655/change-in-diabetic-retinopathy-through-2-years-secondary-analysis-of-a-randomized-clinical-trial-comparing-aflibercept-bevacizumab-and-ranibizumab
#14
Susan B Bressler, Danni Liu, Adam R Glassman, Barbara A Blodi, Alessandro A Castellarin, Lee M Jampol, Paul L Kaufman, Michele Melia, Harinderjit Singh, John A Wells
Importance: Anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME) favorably affects diabetic retinopathy (DR) improvement and worsening. It is unknown whether these effects differ across anti-VEGF agents. Objective: To compare changes in DR severity during aflibercept, bevacizumab, or ranibizumab treatment for DME. Design, Setting, and Participants: Preplanned secondary analysis of data from a comparative effectiveness trial for center-involved DME was conducted in 650 participants receiving aflibercept, bevacizumab, or ranibizumab...
April 27, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/28445077/effect-of-epiretinal-membranes-on-antivascular-endothelial-growth-factor-treatment-for-neovascular-age-related-macular-degeneration
#15
Han Joo Cho, Jae Min Kim, Hyoung Seok Kim, Dong Won Lee, Chul Gu Kim, Jong Woo Kim
PURPOSE: To evaluate the effect of epiretinal membranes (ERMs), detected with spectral-domain optical coherence tomography (SD-OCT), on the outcome of antivascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (nAMD). METHODS: A total of 434 eyes with treatment-naive nAMD were retrospectively included and analyzed. All patients were administered an initial series of 3 monthly loading injections of ranibizumab or aflibercept, followed by further injections as required...
April 26, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28432109/early-response-to-ranibizumab-predictive-of-functional-outcome-after-dexamethasone-for-unresponsive-diabetic-macular-oedema
#16
Maria Vittoria Cicinelli, Michele Cavalleri, Lea Querques, Alessandro Rabiolo, Francesco Bandello, Giuseppe Querques
PURPOSE: To analyse the effects of intravitreal dexamethasone implant in patients suffering from diabetic macular oedema (DME) on the basis of their visual and functional response to antivascular endothelial growth factor (VEGF) loading dose, in order to early shift to corticosteroids in poorly responding patients. DESIGN: Retrospective monocentric study. METHODS: Data of patients with diabetes shifted to 0.7 mg dexamethasone implant after three injections of ranibizumab (RNB) and followed-up to 12 months were reviewed...
April 21, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28427072/anti-vascular-endothelial-growth-factor-injections-the-new-standard-of-care-in-proliferative-diabetic-retinopathy
#17
Xintong Li, Marco A Zarbin, Neelakshi Bhagat
For decades, panretinal photocoagulation (PRP) has been the standard of care for the treatment of proliferative diabetic retinopathy (PDR). The relatively recent advent of anti-vascular endothelial growth factor (VEGF) formulations for intravitreal injection has provided a fresh perspective on PDR treatment, especially in eyes with concurrent diabetic macular edema (DME). The anti-VEGF agent ranibizumab has demonstrated a potentially protective effect on eyes with DME in terms of progression to PDR in the RIDE/RISE trials, as has aflibercept in the VIVID/VISTA trials...
2017: Developments in Ophthalmology
https://www.readbyqxmd.com/read/28427068/intravitreal-steroids-in-diabetic-macular-edema
#18
Rosangela Lattanzio, Maria Vittoria Cicinelli, Francesco Bandello
Over the past decade, great strides have been made in the management of diabetic macular edema (DME). Therapeutic alternatives now include focal/grid laser photocoagulation, vitreo-retinal surgery, and intraocular injection of anti-angiogenic and steroid molecules. Intravitreal administration of steroids represents a fundamental alternative for recalcitrant and naive eyes with DME, especially in those cases when anti-vascular endothelial growth factor (VEGF) agents are contraindicated or a treatment regimen with fewer intravitreal injections is required...
2017: Developments in Ophthalmology
https://www.readbyqxmd.com/read/28427067/intravitreal-aflibercept-in-diabetic-macular-edema-long-term-outcomes
#19
Ugo Introini, Giuseppe Casalino
For decades, macular laser photocoagulation has been the standard of care in the treatment of diabetic macular edema (DME). With the relatively recent advent of anti-vascular endothelial growth factor (VEGF) agents, DME treatment has entered a new era. VEGF is a well-known pro-angiogenic and pro-permeability factor involved in the pathogenesis of DME. VEGF blockade has proven remarkably effective at reducing DME and improving visual acuity (VA) in eyes with center involved DME causing VA loss in several randomized controlled trials (RCTs)...
2017: Developments in Ophthalmology
https://www.readbyqxmd.com/read/28424992/intravitreal-anti-vegf-treatment-for-choroidal-neovascularization-secondary-to-punctate-inner-choroidopathy
#20
T Barth, F Zeman, H Helbig, M-A Gamulescu
PURPOSE: To assess the outcome of patients with choroidal neovascularization (CNV) secondary to punctate inner choroidopathy (PIC) receiving intravitreal anti-VEGF (vascular endothelial growth factor) injections. METHODS: Sixteen eyes of 16 patients diagnosed with CNV secondary to PIC were retrospectively assessed. RESULTS: Eleven women and five men with a mean age of 35 years (SD 11, range 16-56 years) received intravitreal anti-VEGF for PIC-related CNV...
April 19, 2017: International Ophthalmology
keyword
keyword
36614
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"